Enliven Therapeutics, Inc.
ELVN
$18.73
-$0.08-0.43%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.14% | 6.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 17.84% | -0.64% | |||
| Operating Income | -17.84% | 0.64% | |||
| Income Before Tax | -23.14% | -0.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -23.14% | -0.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -23.14% | -0.10% | |||
| EBIT | -17.84% | 0.64% | |||
| EBITDA | -17.91% | 0.64% | |||
| EPS Basic | -22.67% | 3.09% | |||
| Normalized Basic EPS | -18.21% | -0.57% | |||
| EPS Diluted | -22.67% | 3.09% | |||
| Normalized Diluted EPS | -18.21% | -0.57% | |||
| Average Basic Shares Outstanding | 0.39% | 3.30% | |||
| Average Diluted Shares Outstanding | 0.39% | 3.30% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||